VEGFR
2 drugsPredictive biomarker for patient selection in 3 indications
2
Approved Drugs
3
Indications
2
Companies
VEGFR is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 3 indications including Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Medullary Thyroid Cancer. Explore the targeted therapies, indications, testing methods, and companies developing VEGFR drugs below.
Search VEGFR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting VEGFR
VEGFR Indications
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Medullary Thyroid Cancer